Trivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (TIIV)
FLUZONE® HIGH-DOSE  Supplier: Sanofi Pasteur Limited

INDICATIONS:
• Individuals 65 years of age and older living in long term care facilities

The vaccine is not approved for use in those under 65 years of age.

DOSES AND SCHEDULE:
• 1 dose given as 0.5 mL IM.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES AND RE-IMMUNIZATION:
Annually.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of any type of influenza vaccine or to any component of FLUZONE® HIGH-DOSE.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine without another cause being identified.
3. Receipt of a CTLA-4 inhibitor (e.g., ipilimumab) alone or in combination with other checkpoint inhibitors for the treatment of cancer. Inactivated influenza vaccine should be given 8 weeks before starting treatment or 8 weeks after the last dose. For more specific details refer to the BC Cancer Influenza vaccine recommendations.

PRODUCT COMPONENTS:
Potential allergens: egg protein.
Other components: formaldehyde, sodium phosphate-buffered isotonic, sodium chloride solution, Triton® X-100.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
Egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) can be immunized with inactivated or live attenuated influenza vaccine in any setting attended by immunization service providers who are following standard vaccine administration practice.  

^ See Safety Issues Applicable to Influenza Vaccines, 1. Egg Allergic Individuals.
Trivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (TIIV)
FLUZONE® HIGH-DOSE Supplier: Sanofi Pasteur Limited

ADVERSE EVENTS:
Local: pain, swelling, redness.
Systemic: headache, myalgia, fever, malaise.